Podcasts about Metastatic breast cancer

Plant-Based Diet Improves Outcomes in Metastatic Breast Cancer by Citeline

In this raw, refreshing, and beautifully honest episode, Wren, the founder of the Living Our Breast Lives Podcast is joined by the vibrant Bethany Adair—a woman who's not just living with Metastatic Breast Cancer (MBC), but living the f*ck out of life despite it. From the moment she opens up, Bethany invites us beyond the diagnosis and into her world: her passions, her community, her writing, and her unshakable authenticity.We explore the realities of MBC—from diagnosis and treatment to mental health, anxiety, and the emotional exhaustion that comes with being seen as “the strong one.” Bethany shares how she balances joy and grief, hope and hardship, strength and softness—all while building a life filled with meaning and purpose.She also talks about breaking the mold of toxic positivity in the cancer space, and why vulnerability might just be the bravest act of all. As an author, she opens up about how Metastatic Breast Cancer has shaped her voice and the messages she wants to share with the world.Whether you're living with MBC, love someone who is, or just want to hear a powerful story about resilience, identity, and living out loud—this episode is for you. It's real, it's raw, it's relatable, and most importantly—it's a reminder that life is still worth living, even in the messiest, most uncertain moments.Living Our Breast Lives Information:Email: livingourbreastlivespodcast1@gmail.comInstagram: @livingourbreastlivesFounder: Wren MorrobelPersonal Instagram: @wren_morrBethany Adair's Information:Email: Bethany@mygurucancer.comWebsite: www.mygurucancer.comBook: My Guru Cancer: You Don't Have to Fight to Find True Freedom from the C Word (found on Amazon + most online retailers)Instagram: @mygurucancerFacebook: @mygurucancer TikTok: @mygurucancerNewsletter: http://eepurl.com/bySU1X

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:Key Comorbidities in Patients with HR+/HER2- MBCImpact of PolypharmacyRole of APPs in Comprehensive CareRole of CDK4/6 Inhibitors and Other Treatments for HR+/HER2- MBCUtility of RWE dataCommunicating Treatment Options With Patients and CaregiversUnderstanding Patient Goals and Coordinating With the Multidisciplinary Team to Individualize Treatment and Maximize Quality of LifeLink to full program:https://bit.ly/4jCQe38

Dr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00) Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract  Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13) Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract  Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05.  Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06) VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P.  Selective review of trials of oral SERDs in the adjuvant setting (11:27) A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054 CME information and select publications

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QJY865. CME/MOC/NCPD/AAPA credit will be available until May 13, 2026.Navigating the Clinical Integration of TROP2-Targeted ADCs in TNBC and HR+, HER2- Metastatic Breast Cancer: A Customized Learning Journey In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program has been supported by an independent educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QJY865. CME/MOC/NCPD/AAPA credit will be available until May 13, 2026.Navigating the Clinical Integration of TROP2-Targeted ADCs in TNBC and HR+, HER2- Metastatic Breast Cancer: A Customized Learning Journey In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program has been supported by an independent educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QJY865. CME/MOC/NCPD/AAPA credit will be available until May 13, 2026.Navigating the Clinical Integration of TROP2-Targeted ADCs in TNBC and HR+, HER2- Metastatic Breast Cancer: A Customized Learning Journey In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program has been supported by an independent educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QJY865. CME/MOC/NCPD/AAPA credit will be available until May 13, 2026.Navigating the Clinical Integration of TROP2-Targeted ADCs in TNBC and HR+, HER2- Metastatic Breast Cancer: A Customized Learning Journey In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program has been supported by an independent educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00) Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract  Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00) Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25) Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57) Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5. CME information and select publications

Dr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

This featured podcast includes a data review and candid conversation with 4 experts on challenges in the current treatment paradigm for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) due to endocrine resistance. This session occurred during a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025.  ESR1 mutations are a critical mechanism of resistance, spurring the development of next-generation endocrine agents targeting these mutations. These agents including oral selective estrogen receptor degraders (SERDs) and agents with novel mechanisms, including proteolysis-targeting chimeras (PROTACs), which may offer potential improvements over current treatments. This program will review mechanisms of resistance to current endocrine regimens, strategies to overcome this resistance including comparative mechanisms of novel endocrine agents, emerging data from ongoing clinical trials, and expert perspectives on where these new agents may fit into current algorithms.

Send us a textWelcome to the latest Series of Supportive Care Matters, a podcast hosted by Medical Oncologist and International Cancer Survivorship Expert, Professor Bogda Koczwara AM.The landscape of cancer survivorship is evolving before our eyes. As treatment advances allow people with metastatic cancer to live longer, we're witnessing the emergence of a population that exists in what medical oncologist Dr Lori Spoozak calls "the place in between" – not curable but not actively dying.In this eye-opening conversation, researchers Associate Professor Nick Hart and Dr. Andrea Smith (who herself lives with metastatic breast cancer) explore the unique challenges faced by those living with advanced cancer. While survivorship programs have traditionally focused on post-treatment care, metastatic patients are typically on treatment for life, navigating constant healthcare interactions, accumulating side effects and facing the certainty rather than just the fear of disease progression.The discussion reveals how metastatic cancer patients have often fallen through the cracks – excluded from survivorship programs yet not appropriately served by palliative care services that focus primarily on end-of-life needs. This growing population faces what Dr. Smith describes as supportive care needs "on steroids" – intensified physical, psychological, financial and practical challenges that require specialised approaches.Hart and Smith share their ground-breaking work developing the first international standards for metastatic cancer survivorship care, now translated into 14 languages to guide implementation worldwide. They emphasise that improving care requires action on multiple fronts: better education for healthcare professionals, redesigned care models, dedicated peer support programs and recognition that survivorship care is everyone's responsibility rather than the domain of any single provider.Whether you're a healthcare professional, researcher, patient advocate or someone living with cancer, this conversation challenges conventional thinking about survivorship and offers a compelling vision for more inclusive, responsive care. Discover why supporting those living for years with incurable cancer represents both an urgent challenge and a tremendous opportunity to enhance quality of life for this overlooked population.Visit www.oncologynews.com.au for show notes and more information about Supportive Care Matters.This conversation is proudly produced by the Podcast Team at The Oncology Podcast, part of the Oncology Media Group Australia.

- Overview of Metastatic Breast Cancer - Current Standard of Care - New Treatment Approaches - Updates on Clinical Trials - How Clinical Research Increases Your Treatment Options - Biomarkers, Diagnostic Testing & Technologies: Why They Are Important in Informing Treatment Decisions for Metastatic Breast Cancer - Preventing & Managing Treatment Side Effects, Symptom, Discomfort & Pain - Communicating with Your Health Care Team about Quality-of-Life Concerns - The Increasing Role of Telehealth/Telemedicine Appointments - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality of Life Concerns - Questions for Our Panel of Experts

- Overview of Metastatic Breast Cancer - Current Standard of Care - New Treatment Approaches - Updates on Clinical Trials - How Clinical Research Increases Your Treatment Options - Biomarkers, Diagnostic Testing & Technologies: Why They Are Important in Informing Treatment Decisions for Metastatic Breast Cancer - Preventing & Managing Treatment Side Effects, Symptom, Discomfort & Pain - Communicating with Your Health Care Team about Quality-of-Life Concerns - The Increasing Role of Telehealth/Telemedicine Appointments - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality of Life Concerns - Questions for Our Panel of Experts

- Overview of Metastatic Breast Cancer - Current Standard of Care - New Treatment Approaches - Updates on Clinical Trials - How Clinical Research Increases Your Treatment Options - Biomarkers, Diagnostic Testing & Technologies: Why They Are Important in Informing Treatment Decisions for Metastatic Breast Cancer - Preventing & Managing Treatment Side Effects, Symptom, Discomfort & Pain - Communicating with Your Health Care Team about Quality-of-Life Concerns - The Increasing Role of Telehealth/Telemedicine Appointments - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality of Life Concerns - Questions for Our Panel of Experts

In this solo episode, Heather talks about living with metastatic breast cancer over 26 years. Each week, Heather shares profound insights gained from her remarkable 25-year journey as a metastatic breast cancer survivor. Join us as we delve into essential topics like cancer survivorship, where Heather and Larry impart valuable mental health advice and coping strategies for cancer patients. From navigating hospitals to post-treatment tips, Heather's candid and compassionate narrative serves as a beacon of strength. Tune in for an intimate exploration of coping mechanisms, including Heather's personal journey insights, as she imparts wisdom on resilience, hope, and living life to the fullest despite the challenges of metastatic breast cancer. If you or a loved one is seeking authentic guidance, this podcast provides a wealth of information, ensuring that no one faces cancer alone. Check out our newly designed 5 to Thrive Guides at www.heatherjose.com/products. Follow Heather's Socials: Instagram: HeatherbjoseLinkedIn: ⁠ / heatherjose ⁠ Youtube: @ImStillHereCancer Little Pink Houses of Hope Provides Free Vacations for People with Breast Cancer- ⁠https://www.littlepink.org/⁠ ⁠#MetastaticBreastCancer⁠ ⁠#Deconstruct⁠ ⁠#Deconstruction⁠ ⁠#CancerSurvivor⁠ ⁠#ThrivingWithCancer⁠ ⁠#MentalHealthMatters⁠ ⁠#NutritionForWellness⁠ ⁠#MedicalAdvancements⁠ ⁠#MindfulnessJourney⁠ ⁠#ResiliencePodcast⁠ ⁠#PatientAdvocacy⁠ ⁠#TreatmentInsights⁠ ⁠#SurvivorStories⁠ ⁠#PodcastHope⁠ ⁠#CommunitySupport⁠ ⁠#EmpowermentPodcast⁠ ⁠#LivingBeyondDiagnosis⁠ ⁠#PositiveMindset⁠ ⁠#WellnessWednesday⁠ ⁠#CancerAwareness

In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:Common comorbidities and complexities in managing patients with HR+/HER2- MBCTreatment landscape for patients with HR+/HER2- MBCReal-world studies in women with HR+/HER2- MBCMitigation and management of drug interactions and multidisciplinary team coordination treatment selectionPatient goals and coordinating with multidisciplinary team to maximize quality of lifeLink to full program:https://bit.ly/4jCQe38

Featuring an interview with Dr Adam M Brufsky, including the following topics: Case: A woman in her early 50s with ER-positive, HER2-low de novo metastatic breast cancer (0:00) Case: A woman in her late 70s with ER-positive, HER2-low metastatic breast cancer after 5 years of an adjuvant aromatase inhibitor (6:52) Clinical Investigator Survey Results (10:05) CME information and select publications

Dr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer and preexisting medical conditions. CME information and select publications here.

In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:Common comorbidities and complexities in managing patients with HR+/HER2- MBCTreatment landscape for patients with HR+/HER2- MBCReal-world studies in women with HR+/HER2- MBCMitigation and management of drug interactions and multidisciplinary team coordination treatment selectionPatient goals and coordinating with multidisciplinary team to maximize quality of lifeLink to full program:https://bit.ly/4jCQe38

Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics: Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00) Comparing safety profiles of CDK4/6 inhibitors (9:49) Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06) Real-world evidence with CDK4/6 inhibitors (27:31) CME information and select publications

Please visit answersincme.com/BCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses use of TROP2-directed antibody-drug conjugates for the management of hormone receptor–positive, HER2-negative metastatic disease. Upon completion of this activity, participants should be better able to: Identify the available TROP2-directed ADCs for management of HR+, HER2- metastatic breast cancer (mBC); Outline the efficacy and safety of available and emerging TROP2-directed ADCs for HR+, HER2- mBC; and Apply personalization factors to help identify the optimal therapy for each individual patient with HR+, HER2- mBC.

Send us a textJen Byles' Story: A Message That Can't Wait Any Longer This episode has been a long time coming, and I deeply regret not sharing Jen's story sooner—sorry, Jen! And to the women who needed to hear her message earlier, I truly apologize. But the important thing is that it's here now, and it serves as a powerful reminder: don't ignore the signs, check your breasts regularly, and let's normalize this conversation.Jen's mission is to be a voice for young women, an advocate for support, and a beacon of strength for those navigating life with breast cancer—both the individuals facing it and the families standing beside them.Settle in for an inspiring and deeply moving conversation with the incredible Jen Byles.With love,Ria MestizaConnect with Jen via instagram: @jenbyles @fkcancerpodcast @mbcactionaus @walkandtalkcancer

After living with a metastatic breast cancer diagnosis for many years, in 2020 Belinda was in a wheelchair, on oxygen and not expected to live. Facing her own mortality helped Belinda to realize what is most valuable in life… the ability to find peace in the middle of turmoil, the discovery of joy in the smallest of things, to be held in love, to allow ourselves to receive support, to listen to our own wisdom, and to live with meaning and purpose. Belinda has been 'back in harmony' since 2021. With a background in medical science and post-graduate training as a P.S.H. therapist, Belinda drew from both science and spirituality as part of an integrated approach to recovering her wellbeing. Gently healing her own emotional memory was a significant part of Belinda's recovery. See Belinda's interview in the film 'Emotional Healing'  Link to Belinda's "Healing Your Feelings" Blog For more information about practitioner training in P.S.H. therapy visit https://pshtraining.com.au/ __________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube  

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including:Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive metastatic breast cancer and 2 or fewer previous therapiesTreatment sequencing and preferred treatment options in patients with brain metastasesResults from phase III PATINA trial of trastuzumab, pertuzumab, plus endocrine therapy with or without palbociclib in hormone-receptor positive/HER2-positive metastatic breast cancerThoughts on the use of T-DXd earlier in the treatment paradigm in light of recent results from the PATINA trial and highly anticipated results from the DESTINY-Breast09 trialProgram faculty:Stephanie L. Graff, MD, FACP, FASCODirector of Breast Oncology, Brown University HealthCo-Lead, Breast Cancer Translational Disease Research GroupLegorreta Cancer Center at Brown UniversityAssociate Professor of MedicineWarren Alpert Medical School of Brown UniversityProvidence, Rhode IslandLaura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Resources:To access the patient cases associated with this podcast discussion, please visit the program page and register for an upcoming webinar on this topic.

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

Featuring an interview with Dr Komal Jhaveri, including the following topics: Emerging treatment options for advanced ER-positive breast cancer (0:00) Burstein H. Emerging treatment options for advanced ER+ breast cancer. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01 Discussant. Elacestrant real-world progression-free survival for adult patients with ER-positive, HER2-negative advanced breast cancer: A retrospective analysis using insurance claims in the United States (7:28) Swallow E et al. Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: A retrospective analysis using insurance claims in the United States. San Antonio Breast Cancer Symposium 2024;Abstract P3-10-08. Ongoing clinical trials involving oral SERDs (9:03) Kaklamani V et al. ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC): An open-label multicenter phase 2 study. San Antonio Breast Cancer Symposium 2024;Abstract P2-08-20. An adjuvant endocrine-based therapy study of camizestrant (AZD9833) in ER+/HER2- early breast cancer (CAMBRIA-2). NCT05952557 Bardia A et al. ELEGANT: Elacestrant versus standard endocrine therapy in women & men with node-positive, estrogen receptor-positive, HER2-negative, early breast cancer with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study. San Antonio Breast Cancer Symposium 2024;Abstract P2-08-21. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer (13:48) Lloyd MR et al. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol 2024;21(10):743-61. Abstract CME information and select publications

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

Featuring an interview with Dr Komal Jhaveri, including the following topics: Imlunestrant, an oral selective estrogen receptor degrader (SERD), with and without abemaciclib for ER-positive, HER2-negative advanced or metastatic breast cancer (0:00) Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2024;[Online ahead of print]. Abstract Rugo HS et al. Elacestrant abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC). San Antonio Breast Cancer Symposium 2024; Abstract PS7-07. Elacestrant for ER-positive, HER2-negative metastatic breast cancer with ESR1-mutated tumors: Subgroup analyses from the Phase III EMERALD trial by duration of prior endocrine therapy with a CDK4/6 inhibitor and in clinical subgroups (7:40) Bardia A et al. Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res 2024;30(19):4299-309. Abstract Pharmacokinetics and safety of imlunestrant in patients with hepatic impairment (11:25) Wang XA et al. Evaluation of pharmacokinetics and safety of imlunestrant in participants with hepatic impairment. San Antonio Breast Cancer Symposium 2024;Abstract P4-10-07. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer (13:15) Lloyd MR et al. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol 2024;21(10):743-61. Abstract CME information and select publications

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

In today's episode, we had the pleasure of speaking with Aditya Bardia, MD, MPH, FASCO, about the FDA approval of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the treatment of adult patients with unresectable or metastatic, hormone receptor–positive, HER2-low or -ultralow breast cancer, as determined by an FDA-approved test, that has progressed on at least 1 endocrine therapy in the metastatic setting. Dr Bardia serves as a professor in the Department of Medicine in the Division of Hematology/Oncology and is the director of Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center. In our exclusive interview, Dr Bardia discussed the significance of this approval, findings from the pivotal DESTINY-Breast06 trial (NCT04494425), and what this new indication for T-DXd means for the future of HER2 testing in breast cancer.

In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights and frequently asked questions related to the CDK4/6 inhibitors used to treat patients with early and metastatic hormone receptor (HR)–positive/HER2-negative breast cancer from a live program held in January 2025. Key clinical pearls include:Adjuvant treatment selection recommendations for patients with HR-positive/HER2-negative early breast cancer based on disease and patient characteristics as well as the latest data and guidelines presented by Dr. GradisharTherapeutic strategies for patients diagnosed with HR-positive/HER2-negative metastatic breast cancer (MBC) presented by Dr. AbrahamAddressing challenges related to CDK4/6 inhibitor adherence and adverse event mitigation presented by Dr. SpringPresenters:Jame Abraham, MD, FACPEnterprise Chair and Professor of MedicineDepartment of Hematology and Medical OncologyCleveland ClinicCleveland, OhioWilliam J. Gradishar, MD, FACP, FASCOBetsy Bramsen Professor of Breast OncologyRobert H. Lurie Comprehensive Cancer CenterNorthwestern UniversityChicago, IllinoisLaura Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, MassachusettsLink to full program including downloadable slides and on-demand webcasts: https://bit.ly/4b5GFqqTo claim credit for listening to this episode, please visit the podcast online at the link above.

In today's episode, supported by Genentech, we had the pleasure of speaking with Komal Jhaveri, MD, FACP, about the clinical use of inavolisib (Itovebi) for patients with hormone receptor (HR)–positive, PIK3CA-mutated, locally advanced or metastatic breast cancer. Dr Jhaveri is section head of the Endocrine Therapy Research Program, clinical director of the Early Drug Development Service, and the Patricia and James Cayne Chair for Junior Faculty at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Dr Jhaveri discussed the importance of having a PI3K inhibitor available for the treatment of patients with HR-positive metastatic breast cancer, advice for managing inavolisib-related adverse effects, and best practices for early biomarker testing in patients with breast cancer.

In our exclusive interview, Dr Bardia discussed the significance of this approval, pivotal findings from the phase 3 TROPION-Breast01 trial (NCT05104866), the clinical relevance of being able to improve progression-free survival and quality of life with Dato-DXd compared with standard chemotherapy, and key considerations for sequencing antibody-drug conjugates.

Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here

Featuring an interview with Dr Seth Wander, including the following topics: Therapy selection after CDK4/6 inhibitor failure: A review of current and investigational treatment for HR-positive, HER2-negative breast cancer Astore S et al. A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors' failure: A review of current and investigational treatment for HR+/Her2- breast cancer. Crit Rev Oncol Hematol 2024;204:104535. Abstract (0:00) A preoperative window-of-opportunity study of the oral SERD imlunestrant for newly diagnosed ER-positive, HER2-negative localized breast cancer Neven P et al. A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from the EMBER-2 Study. Clin Cancer Res 2024;30(23):5304-13. Abstract (3:30) An assessment of an exosome-based ESR1-monitoring RT-qPCR kit that detects acquired resistance variants in liquid biopsy samples Statt S et al. An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples. ESMO 2024;Abstract 420P. (7:08) CME information and select publications

Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here

On this episode of The CA Media Podcast, Kim and I dives into our podcast without a topic but an emotional subject comes about and we dive into that topic and this thus led to one of the most emotional episodes ever produced. To learn more about Metastatic Breast Cancer, click here: https://www.pennmedicine.org/cancer/types-of-cancer/breast-cancer/types-of-breast-cancer/metastatic-breast-cancer#:~:text=Metastatic%20breast%20cancer%20is%20always,%2C%20bones%2C%20liver%20and%20lungs. We thank Pennmedicine.org for the information To follow Kim: Instagram: https://www.instagram.com/_milkeywayy X: https://x.com/_milkywayy Visionary Minds Public Relations and Media is a supporting sponsor of the CAMedia Podcast Make sure you get your Publicity, Digital Marketing, Writing, Media Consulting Services at visionarymindsny@gmail.com where Tammy Reese is the owner.

Featuring an interview with Dr Seth Wander, including the following topics: The clinical utility of ESR1 mutations in HR-positive, HER2-negative advanced breast cancer Grinshpun A et al. The clinical utility of ESR1 mutations in hormone receptor-positive, HER2-negative advanced breast cancer. Hematol Oncol Clin North Am 2023;37(1):169-81. Abstract (0:00) Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy for ER-positive, HER2-negative advanced breast cancer Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Phase Ia/Ib EMBER study. J Clin Oncol 2024;[Online ahead of print]. Abstract (6:01) EORTC-2129-BCG: Elacestrant for ER-positive/HER2-negative breast cancer patients with ctDNA relapse Ignatiadis M et al. EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA). ESMO 2024;Abstract 338TiP. (8:20) CME information and select publications  

Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here

Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here

A registered nurse for 35 years, Maree is a passionate health care professional that splits her working life between a cardiac catheterization lab and running an integrative nurse-led therapy practice from home. The diagnosis of Metastatic Breast Carcinoma brought a deep inward journey to deepen self awareness and the realisation that we must fundamentally transform the way in which we provide cancer therapy. Maree has had no evidence of disease for almost 5 years.  Contact Maree at 1mareesmith@gmail.com Resources shared: Neuro Integration Systems (NIS)- Dr Allen Phillips - neurolinkglobal.com Salvesterol contact is https://www.salvacare.co.nz  Iscador (mistletoe) contact weleda.co.nz  ________________________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram  YouTube

Catch up on new data from San Antonio on innovative treatments and patient-centered management strategies for estrogen receptor (ER)-positive metastatic breast cancer (MBC). Credit available for this activity expires: 01/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002163?ecd=bdc_podcast_libsyn_mscpedu

Featuring perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O'Shaughnessy and Dr Sara M Tolaney, including the following topics: Introduction (0:00) Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Dr Krop (10:17) Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr Tolaney (37:54) Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Kalinsky (53:59) Tolerability Considerations with Approved and Investigational Antibody-Drug Conjugates — Dr O'Shaughnessy (1:14:16) Other Important Care Considerations for Patients with mBC — Dr Hamilton (1:41:30) CME information and select publications

Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O'Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/SABCS2024/mBC).

Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O'Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer.

Enjoy Living Our Breast Lives' last podcast episode of the year! Join Wren Morrobel, founder of the Living Our Breast Lives podcast, and Caroline Johnson, the founder of Twisted Pink, a nonprofit dedicated to funding critical research for Metastatic Breast Cancer! Together, they delve into the nonprofit's framework, the impact of allyship in advocating for the MBC community as an early-stage survivor, and their shared takeaways from the 2024 San Antonio Breast Cancer Symposium!Caroline Johnson—a patient advocate, wife, mom of three, and an 11-year stage three breast cancer survivor—shares her inspiring mission to direct critical funding toward Stage IV Metastatic Breast Cancer research. Her passion for advocacy stems from years of championing her son, born with a rare genetic deletion called BBSOAS. These profound medical and healthcare experiences not only shaped her advocacy journey but also empowered her to navigate her own breast cancer diagnosis with strength and determination.Caroline's unwavering dedication to supporting the MBC community shines through every time she speaks. She remains a passionate advocate for improved healthcare systems and policies benefiting individuals with rare diseases and cancer. As an early-stage survivor, she feels grateful to continue preventative treatment to this day, stay informed about clinical trials, and emphasize the vital role research plays in advancing cancer care.Living Our Breast Lives Information:Email: livingourbreastlives@gmail.comInstagram: @livingourbreastlivesFounder: Wren MorrobelPersonal Instagram: @wren_morrCaroline Johnson's Contact Information:Email: cvanjohnson73@twistedpink.orgWebsite: twistedpink.orgInstagram: @twistedpinkorgFacebook: Twisted PinkLinkedin: linkedin.com/company/twisted-pink-incYoutube: youtube.com/@TwistedPink

In this episode of Empowered Intimacy: Getting Your Sexy Back After Breast Cancer, Melissa Berry and her co-host, Deltra, talk about the often-overlooked topic of sex and intimacy after a breast cancer diagnosis. Building on their previous discussions about dating and relationships post-cancer, they share the real challenges that chemotherapy and medications can bring, such as low libido, vaginal dryness, and pain during intercourse. They also emphasize the importance of emotional intimacy and share practical strategies for reconnecting with your partner, fostering a deeper bond, and navigating these obstacles together. Tune in for an authentic conversation, just like you're overhearing two friends talk about overcoming the physical and emotional hurdles of intimacy after breast cancer. Thank you to Daiichi Sankyo for making this episode possible!